Ophthotech (NASDAQ: OPHT) is one of 286 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its competitors? We will compare Ophthotech to similar businesses based on the strength of its profitability, institutional ownership, analyst recommendations, dividends, earnings, valuation and risk.
Valuation and Earnings
This table compares Ophthotech and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Ophthotech||$50.91 million||-$193.42 million||2.02|
|Ophthotech Competitors||$284.49 million||$34.10 million||79.87|
Volatility and Risk
Ophthotech has a beta of 1.58, indicating that its stock price is 58% more volatile than the S&P 500. Comparatively, Ophthotech’s competitors have a beta of 6.06, indicating that their average stock price is 506% more volatile than the S&P 500.
Insider and Institutional Ownership
62.5% of Ophthotech shares are held by institutional investors. Comparatively, 49.9% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 2.0% of Ophthotech shares are held by insiders. Comparatively, 16.9% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This table compares Ophthotech and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings for Ophthotech and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Ophthotech currently has a consensus price target of $4.00, indicating a potential upside of 26.18%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.53%. Given Ophthotech’s competitors stronger consensus rating and higher possible upside, analysts plainly believe Ophthotech has less favorable growth aspects than its competitors.
Ophthotech competitors beat Ophthotech on 9 of the 13 factors compared.
Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness. Its product candidates include Fovista and Zimura. Fovista is designed to target platelet derived growth factor (PDGF) in combination with anti-vascular endothelial growth factor (VEGF) drugs to disrupt the formation of abnormal new blood vessels in wet AMD. Zimura targets complement factor C5, a central component of the complement cascade. The Company has initiated a Phase II/III clinical trial investigating Zimura for treatment of geographic atrophy.
Receive News & Ratings for Ophthotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech and related companies with MarketBeat.com's FREE daily email newsletter.